

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

RECEIVED

JUN 15 2004

File Information Unit

In re Application of

Strachan

Application Number

09/276268

Filed

3/25/99

Paper No.

#10

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____, line _____,

United States Patent Number 6242419, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public (see 37 CFR 1.14(c) if applicant) but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Signature

Victoria Kessinger

Typed or printed name

Registration Number, if applicable

723330-6011

Telephone Number

Date

6/15/04

RECEIVED

Approved

JUN 15 2004

(initials)

Unit:

File Information Unit

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006242419B1

(12) **United States Patent**
Strachan et al.

(10) **Patent No.:** **US 6,242,419 B1**
(45) **Date of Patent:** **Jun. 5, 2001**

(54) **COMPOSITIONS ISOLATED FROM STROMAL CELLS AND METHODS FOR THEIR USE**

(75) **Inventors:** Lorna Strachan; Matthew Sleeman; Nevin Abernethy; Rene Onrust; Anand Kumble; Greg Murison, all of Auckland (NZ)

(73) **Assignee:** Genesis Research & Development Corporation Ltd., Parnell (NZ)

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** 09/383,586

(22) **Filed:** Aug. 26, 1999

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/276,268, filed on Mar. 25, 1999, now abandoned.

(51) **Int. Cl.⁷** A01N 37/18; A61K 38/16; A61K 38/00

(52) **U.S. Cl.** 514/12; 514/2; 514/8; 530/380

(58) **Field of Search** 514/2, 8, 12; 530/380

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

9963088 12/1999 (WO).
0024756 5/2000 (WO).

OTHER PUBLICATIONS

GenPept Assession No. CAB90552.
GenPept Assession No. AAC78827.
GenPept Assession No. AAC64321.
GenPept Assession No. AAD09175.
GenPept Assession No. AAB30638.
GenPept Assession No. CAA53271.
GenPept Assession No. CAA41209.
GenPept Assession No. AAB25535.

GenPept Assession No. CAB65272.

GenPept Assession No. AAF03400.

GenPept Assession No. AAF20364.

GenPept Assession No. BAA91786.

GenPept Assession No. AAB42225.

GenPept Assession No. AAC15584.

GenPept Assession No. AAF69825.

GenPept Assession No. BAA18909.

GenPept Assession No. AAC83205.

GenPept Assession No. CAB55955.

Swiss-Prot Assession No. P14730.

Swiss-Prot Assession No. P53104.

Swiss-Prot Assession No. Q14956.

Swiss-Prot Assession No. Q99969.

PIR Assession No. T17265.

PIR Assession No. S38579.

Gruss, Hans-Jürgen and Dower, Stephen K., "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas", *Blood*, vol. 85, No. 12, pp. 3378-3404 (Jun. 15, 1995).

Banner, David W., et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation", *Cell*, vol. 73, pp. 431-445 (May 7, 1993).

Maher, Pamela "p³⁸ Mitogen-activated Protein Kinase Activation Is Required for Fibroblast Growth Factor-2-stimulated Cell Proliferation but Not Differentiation", *The Journal of Biological Chemistry*, vol. 274, No. 25, pp. 17491-17498 (Jun. 18, 1999).

Primary Examiner—David Saunders

Assistant Examiner—Amy DeCloux

(74) **Attorney, Agent, or Firm**—Janet Sleath; Ann W. Speckman

(57) **ABSTRACT**

Isolated polynucleotides encoding polypeptides expressed in mammalian fcn -/- lymph node stromal cells are provided, together with expression vectors and host cells comprising such isolated polynucleotides. In certain embodiments such polynucleotides encode members of the fibroblast growth factor receptor family. Methods for the use of such polynucleotides and polypeptides are also provided.

7 Claims, No Drawings